Body Weight Monitoring
Objective: Track weight loss in transgenic mice receiving coenzyme Q10 and/or remacemide treatment to assess therapeutic effects on disease progression
This is a Body Weight Monitoring protocol using mouse as the model organism. The procedure involves 3 procedural steps, 1 equipment items, 2 materials. Extracted from a 2002 paper published in Journal of Neuroscience.
Model and subjects
mouse • R6/2 and N171-82Q transgenic • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Baseline weight measurement • Administer oral treatment • Monitor body weight
Primary readouts
- Body weight loss progression
- Survival time
- Development of motor deficits
- Cerebral atrophy
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Baseline weight measurement
Measure initial body weight of transgenic mice prior to treatment initiation
Note: Baseline measurement needed to track weight loss progression
View evidence from paper
“weight loss in transgenic mice receiving treatment”
Administer oral treatment
Provide oral administration of coenzyme Q10 and/or remacemide to transgenic mice
Note: Combined treatment or single compound administration
View evidence from paper
“oral administration of either coenzyme Q 10 or remacemide significantly extended survival”
Monitor body weight
Regularly measure and record body weight of treated mice throughout the experimental period
Note: Weight loss is a key outcome measure for disease progression
View evidence from paper
“delayed the development of motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions”